BeiGene, Celgene Ink Up-to-$1.393B Cancer Immunotherapy Deal – Genetic Engineering & Biotechnology News
|
BeiGene, Celgene Ink Up-to-$1.393B Cancer Immunotherapy Deal
Genetic Engineering & Biotechnology News Celgene will take a 5.9% stake in BeiGene in an up-to-$1.393 billion cancer immunotherapy deal that will catapult the U.S.-based biotech giant to a top position in programmed death protein-1 (PD-1) checkpoint inhibitors, the companies said today … |
|
Shire Submits Application To US FDA For Gene Therapy For Hemophilia
Interactive Investor The company said the application, which was based on the results of pre-clinical and phase one studies, to the FDA represented the “latest step forward for Shire’s gene therapy program, which shows promise for both hemophilia A and B populations”. Shire submits investigational New Drug Application to FDA for Gene …Nasdaq BRIEF-Shire submits IND application for gene therapy candidate SHP654Reuters |
|
CRI’s 2017 Immunotherapy Patient Series Launches July 8 in San Francisco
Immuno-Oncology News Registration is now open for the 2017 Immunotherapy Patient Summit Series, a set of free half-day events in five U.S. cities focusing on immunotherapy and clinical trials, says the Cancer Research Institute (CRI). CRI held its first Immunotherapy … |
New Scientist |
CRISPR gene editing technique is probably safe, study confirms
New Scientist By Michael Le Page. As you were. In May, a study claimed that the revolutionary CRISPR gene editing technique can cause thousands of unwanted and potentially dangerous mutations. The authors called for regulators to reassess the safety of the technique. CRISPR’s high costs may limit development of gene therapy drugsGenetic Literacy Project |
Genetic Literacy Project |
CRISPR’s high costs may limit development of gene therapy drugs
Genetic Literacy Project “I’m not even sure that many of these gene therapies will work, and not all medicine is worth the price.” But if these technologies become broadly used, especially in altering T cells for cancer, payers won’t meet the demands of steep prices, and … |